Filing Flows › Coya Therapeutics (COYA) › Q1 2025
Coya Therapeutics (COYA) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 13, 2025
Coya Therapeutics (COYA) reported revenue of $258K for the first quarter 2025 (Q1 2025), +103% from a year earlier and up 132-fold from the quarter before.
Coya Therapeutics, Q1 2025: revenue $258K (+103% year over year), net loss $7.3M, operating cash flow −$2.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $258K | 132× | +103% |
| Operating profit | −$7.7M | — | — |
| Net earnings | −$7.3M | — | — |
| Operating cash flow | −$2.8M | — | — |
What changed
Revenue was $258K in Q1 2025, up 103% year over year and up 13111% from the previous quarter.
Operating costs exceeded revenue by $7.7M, an operating margin of -2976.9%. Total costs grew 41% against revenue growth of 103%. The fastest-growing cost line was Research & development (+66%). The quarter ended with a net loss of $7.3M, wider than the previous quarter's $2.9M loss.
Operating cash flow was −$2.8M. Non-cash charges added back $7K of depreciation and $1.1M of share-based compensation. Working capital and other items added $3.4M.
Questions
What was Coya Therapeutics' revenue in the first quarter 2025?
Coya Therapeutics (COYA) reported revenue of $258K for the first quarter 2025 (Q1 2025), +103% from a year earlier and up 132-fold from the quarter before.
Source: Coya Therapeutics 10-Q on SEC EDGAR.